Last update Oct. 4, 2020
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Ondansetron is also known as
Ondansetron in other languages or writings:
Main tradenames from several countries containing Ondansetron in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 60 | % |
Molecular weight | 293 | daltons |
Protein Binding | 75 | % |
VD | 2.2 | l/Kg |
Tmax | 1.5 | hours |
T½ | 3 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Ondansetron is a 5-HT3 receptor antagonist with antiemetic activity.
It is used in the control and prevention of nausea and vomiting.
Administered intravenously, intramuscularly, orally or rectally in one or two doses per day.
Since the last update, we have not found published data on its excretion in breastmilk.
Its high volume of distribution and short half-life make it unlikely that it will be excreted in milk in significant quantities.
It is considered by experts to be safe and of choice in breastfeeding (Reece-Stremtan 2017, Rowe 2016) and probably compatible by prestigious medical associations (Mahadevan 2006).
Its use is safe in children between 1 and 24 months (Khalil 2005).
Furthermore, use after a cesarean does not affect a positive start to breastfeeing (Uerpairojkit 2016) or the health of the baby (Nallam 2017, Elkomy 2015), or the production of prolactin (Hale 2017 p729, Lissoni 1994).